The global RNA sector is entering a defining decade. mRNA and RNA-based therapeutics, validated at scale during the pandemic, are now expanding rapidly into oncology, rare disease, and precision medicine. For nations aiming to lead this megatrend rather than follow it, the window to build durable advantage in research, manufacturing, and workforce is open now.
Australia is unusually well placed to seize this opportunity if we act now. A 43.5% refundable R&D tax incentive, co-investment through the Biomedical Translation Fund and the Medical Research Future Fund, and world-class NCRIS infrastructure sit alongside one of the fastest clinical trial pathways globally: under the CTN scheme, most trials can commence in around five weeks, with no separate US IND or EU CTA required. Twenty-two Australian universities rank among the world's top 400, anchoring a research base capable of moving RNA science from bench to trial faster than almost anywhere else.
RNA Australia (RNAA) exists to connect this ecosystem end to end. RNAA's reach extends through NSW and the ACT, across Australia and New Zealand, and into the global RNA community, connecting Australia outward without duplicating what already exists. Our work spans four pillars: advanced manufacturing excellence, translation, engagement, and enablement – and focuses on training and capability building, ecosystem events, regulatory engagement, and attracting funding, investment and talent into the sector.
The final piece is manufacturing. The NSW RNA Research and Manufacturing Facility – a $96 million investment funded through the Office of the NSW Chief Scientist and Engineer and operated by Aurora Biosynthetics at Macquarie University – opened in April 2026 and is now moving through validation ahead of full operation. Its integrated drug substance and drug product model breaks from the conventional split-site approach, reducing complexity, cost, and timelines for projects moving through the pipeline, and closes the gap that has historically stalled promising Australian RNA research before it reaches the clinic: a continuous pathway from laboratory through pre-GMP and GMP manufacturing to trial.
This talk brings these threads together – the global opportunity, Australia's regulatory and research advantages, RNAA's connective role across the ecosystem, and the manufacturing pathway now coming online – to make the case that Australia is positioned not just to participate in the RNA megatrend, but to help lead it.